BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.80
-0.56 (-0.72%)
At close: Nov 17, 2026, 4:00 PM EST
76.76
-0.04 (-0.05%)
After-hours: Nov 17, 2026, 5:52 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Three near-term opportunities include an imminent LGMD2I launch and 2027 regulatory decisions for infigratinib and encaleret. ATTRUBY real-world findings and planned studies support its differentiation, while management is focused on launch execution and broader pipeline indications.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, we're going to get started. My name is Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining us on day one of our London Healthcare Conference, and it's my pleasure to have the Co-founder and CEO of BridgeBio, Neil Kumar. Welcome, Neil.

Neil Kumar
Co-founder and CEO, BridgeBio

Thank you, Andrew.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Maybe to start, you've obviously had a nice series of positive developments over the past year, or past two years, knock on wood. Talk about what you've accomplished, what you've achieved at BridgeBio so far, and walk us through the major milestones over the next year that could be helpful to level set our discussion.

Neil Kumar
Co-founder and CEO, BridgeBio

Sure. Well, thanks again for the time, and thanks to Phil Ross as well for having us here at the conference again this year. As you say, BridgeBio is at a unique period right now because we have three impending launches in the next seven months or so, and that buttresses against now annualizing over $1 billion of ATTRUBY's growth, and we continue to focus there, both on the R&D side, as well as on the commercial side as well. Writ large, we have a launch hopefully in the next couple weeks in LGMD2I, which we can talk a little bit about. In February, we have an anticipated PDUFA for infigratinib for achondroplasia, and then shortly after that, PDUFA date for encaleret for use in ADH1.

We have several ongoing clinical trials. I think the biggest of which is our CHP phase III that should read out at the end of 2027, early 2028. Happy to talk about all of that and more as we go through.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. To be clear, that's the hypoPTH-

Neil Kumar
Co-founder and CEO, BridgeBio

That's right.

Andrew Tsai
Senior Biotech Analyst, Jefferies

trial. Okay. Perfect. I'll get to that.

Neil Kumar
Co-founder and CEO, BridgeBio

Which I think is underappreciated.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Understood.

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Starting with ATTRUBY, not too many questions because I do also want to focus on the pipeline today too, but to start with ATTRUBY. The messaging has been to get first-line market share. I think you've guided to like 30%-40% at peak. Right now, maybe 25% plus type market share. I guess, why not more than that if your messaging is to have a superior stabilizer, and would you be, feel prepared to revise your peak sales penetration over time kind of thing?

Neil Kumar
Co-founder and CEO, BridgeBio

Always prepared to do that. Most of our insights in and around peak year sales and share come from analogs, studies of analogs. We've studied about 1,040 different launches. We look at variance over time. It just tends to be, especially in the U.S., that if you're a second mover, you tend not to get more than 30%, 35% share. Obviously, we've outperformed that in Europe, where we're the leading brand. I think if all things were equal, we would be the leading brand in the U.S. as well, but all things are not equal, as you well know, just in terms of some of the different economics in the channel.

For us, it really starts with the clinical differentiation, and we're really now trying. Double-blind head-to-heads are not possible these days, so we're really trying to build that real-world evidentiary dataset to show superiority of acoramidis as it compares to tafamidis. Obviously, it's the only near-complete stabilizer, but building on that, you saw just two publications that we're quite proud of in the context of real-world evidence. One using Komodo data, which showed about a 34% relative risk reduction on hospitalization as compared to tafamidis, stat sig. The second was on Epic COSMOS, where we showed an 18% reduction in death and a 27% reduction in hospitalization, again, statistically significant as compared to tafamidis.

I think what's very heartening there is the large Ns associated with each of those studies, the statistical significance, and the early separation of those curves, congruent with what we're seeing in terms of the kidney signature, which we can get into as well. I think a lot of exciting science, and we're doubling down on R&D there as well. We just kicked off a cardiac remodeling phase III-b/IV. We've got our ACT-EARLY primary prevention study. I think we're, of any of the sponsors, really doing more in terms of interrogating novel aspects of the medicine in terms of our phase IV studies.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Right. I find it notable in the real-world studies, I think it was a more contemporary population too.

Neil Kumar
Co-founder and CEO, BridgeBio

That's right.

Andrew Tsai
Senior Biotech Analyst, Jefferies

The past two years, so I think that's notable.

Neil Kumar
Co-founder and CEO, BridgeBio

SGLT2I use was contemporary, as you say. Diuretic intensification was another thing we looked at and were superior on. Yes, it was the, quote-unquote, "modern population.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. As I reflect over the past year on the ATTRUBY launch, we had to deal with this whole Pfizer settlement with the generics, VYNDAMAX, their second version of tafamidis. On my side, investors are discussing, or we're automatically thinking there will be some kind of erosion to ATTRUBY come 2031. In your view, what's your stance on that position from investors? Do you think you can actually grow through a generic VYNDAMAX and have sales of ATTRUBY actually go up during that period?

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, I mean, we do. We presented, I think, various aspects of the argument in the past. I would say it really comes down to three things. First and foremost, it is clinical differentiation. We believe we have a better drug product. If it were the same and something was generic, then I don't think it's ethical to push your product forward from that standpoint. The second is, I think, the dramatically underestimated economics in the channel. Patient copays are not going to change between a generic and a branded drug. It's going to be $2,000 for a vast majority of the patients that we serve. People forget that CMS reinsurance is 40% on generics versus 20% on a branded drug.

The economics are not going to be all that different between the two, and it's very hard to step in this category because effectively, you're looking at patients that are very sick. Every minute matters for these patients. You're trying to ward off deleterious deposition of this amyloidotic plaque, and so I think it would be very easy for a physician who would want to be on acoramidis, to put their patient on acoramidis, to put them on. But I think we always go back to the analogs, right? We've modeled some 59 different LOE events over the course of the last 20 years, and you can look at anything from son of Gleevec to the Prilosec category to factor Xa's to statins.

It is very rare that the genericization of one brand means the genericization of the entirety of the category. What we saw in 80%-plus of those cases was continued growth. I do think Pfizer will defend their brand with their small molecule tablet out to 2041, which is where our IP goes right now as well, until we bring our once-daily. We will just have to see, because oftentimes, if it is going to go LOE in 2031, you would see a diminution in the way they are resourcing the brand.

This is a very promotion-sensitive category in the U.S. I actually think that is an opportunity for us to grow even further than what the analog suggests so far. We will have to see. We are very confident in the performance of the brand post 2031.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. If that happens, it is a lot of tail value to the ATTRUBY franchise. Okay. Another dynamic this year was the whole silencer class. I think the whole debate around whether silencers are first line maybe has subsided after the CARDIO-TTRansform. Stabilizer should be the first-line go-to therapy. In the very recent, I guess, recent news is the 340B reform, which to me obviously impacts Alnylam. In your view, does it hurt ATTRUBY in any way?

Neil Kumar
Co-founder and CEO, BridgeBio

No, we are not buy and bill or on Part B. I will not make too much of a big deal out of this. I think it is just generally a tailwind for us through time. I never like to see these aberrant economics driving usage, but I think there were certain institutions that were heavily using the buy and bill opportunity. I think that that will obviously be degraded over some time, which should be an opportunity for ATTRUBY and for BEYONTTRA.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. So congratulations on the execution so far. Hopefully more to come. We will shift gears to the pipeline. But before we actually begin that, as I have listened to you during the conference calls over the past few quarters, I do sense frustration towards the stock price overall.

Neil Kumar
Co-founder and CEO, BridgeBio

Turn you off, yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yeah. Why do you think the company, big picture, is highly undervalued in the grand scheme of things? Where is the disconnect between investors and the BridgeBio thesis?

Neil Kumar
Co-founder and CEO, BridgeBio

I think right now, probably primarily driving from two areas. One is that we are just not getting credit for these impending launches. I think they are still show-me stories, despite what we have been able to do with ATTR cardiomyopathy. I think in part that is because it feels disjointed. Although we see these things as either first-in-class or best-in-class launches in the Mendelian space, targeting well-described conditions at their source, I think with very strong data sets, it is hard to put together the opportunity when we have one sales force in cardiovascular, one sales force in neuromuscular, one in endocrine. I think we have to prove that for investors to capture that value, and I think we will over the course of the coming six to 12 months.

The second is honestly, I think, a dramatic underappreciation for what these molecules, the existing molecules in our pipeline that will be approved or are approved, can do in other indications. I think it starts with actually the hypoPTH opportunity within encaleret. Obviously, we have talked broadly about the kidney signal that we observed with ATTRUBY and going into a hyperproteinuric set of orphan diseases. We are going into SHOX and Turner, I think, as we talked about on our last earnings call with infigratinib, should it be approved for achondroplasia. Those are very, very large marketplaces. I think there is a lot of opportunity for us to continue to excavate our already approved or soon-to-be-approved products, and I do not think there is anything in NPV models right now on that.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yes. I want to say earlier in the year, maybe last year though, you said you wanted to be this, I am paraphrasing, premier mid-cap company. Do you think your assets and the indication expansions are enough to get you there, or do you think you want to bring in more to become that top mid-cap company?

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, I do not remember saying that.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay.

Neil Kumar
Co-founder and CEO, BridgeBio

Certainly, we want to be a leader in rare diseases, and to really be a beacon for patients across the board. That means that we need to continue to do what we are doing in our pipeline. Then obviously, we have got off-balance sheet efforts like GondolaBio and others where we continue to prosecute science and medicine that is important to patients. For the time being, we are very focused on execution. That is really going to be what the near future looks like, and Gondola will finance separately and we will move forward from there. Obviously, there is a close relationship between all of these companies, and we are always looking for opportunities to continue to be able to grow the franchise to help more patients.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Perfect. Moving on to LGMD, approval should be within the next week or two.

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, any time now.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Can we expect you to host a conference call for that? Is it a simple press release? Maybe talk about how you're disclosing the potential approval, and do you disclose a price that day, for instance?

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, so we'll have to disclose the price. We will probably do a call that day. We're just excited to get the information out to physicians just as soon as we have it. We're in the late stages now, obviously. I think one of the debates that has come up already this morning is, will we get accelerated approval or full approval? Our view continues to be that the data are strong enough such that we should gain full approval. You probably saw just a couple of weeks ago that we were able to look at the last, I think, remaining important endpoint beyond pulmonary and ambulatory function, which was cardiovascular function, and we showed that 100% of patients were able to normalize their troponin I levels at 12 months. So this is really a remarkable drug product. You're talking about a declining placebo, an inclining set of functions-

Andrew Tsai
Senior Biotech Analyst, Jefferies

Right

Neil Kumar
Co-founder and CEO, BridgeBio

on ambulation, breathing, and the like, and obviously a biochemical signature which is really targeting that causal driver and reversing it. We're excited about that, and we've been to, I think, 95% plus of the MDA centers now to educate on the product. It'll be, I think, hopefully a launch where we capture some bolus and then continue to build from there.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. That was actually my next question. For me personally, I feel like it could be a bolus of a launch. But I think you guys have said maybe 500 you've identified. Within the first year, do you think you can capture most of those 500, or does it take a little bit more time? Can you talk us through the shape of the curve?

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, I mean, these patients tend to come in twice a year, and it's hard to anticipate precisely when they would be coming in, given the news. But our hope is that we will capture some front-end bolus, and then it would be a fairly steady incline over time. I think you could liken it to some of the launches in rare, like Bardet-Biedl or Dystrophic Epidermolysis Bullosa, that type of thing, because I think this is first in class and obviously very compelling data.

The real question is, how do we start to interrogate that longer tail that may be sitting out in the community, that may be idiopathic LGMD or maybe Becker muscular dystrophy, and how do we, in concert, get diagnostic testing to be more readily used? But we have strategies around that, and we're excited to build our capabilities there.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Understood. Ultimately, maybe a 2,000-2,500 patient TAM, U.S. TAM?

Neil Kumar
Co-founder and CEO, BridgeBio

That's right.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay.

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, that's right.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Perfect.

Neil Kumar
Co-founder and CEO, BridgeBio

And a little larger in Europe.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay.

Neil Kumar
Co-founder and CEO, BridgeBio

Because there is a founder effect, so yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Cool. Okay. And so the same compound is also going after, in my notes, LGMD2U, LGMD2M, Fukuyama. Out of curiosity, do you start phase IIIs immediately for those new indications, or how does this all work?

Neil Kumar
Co-founder and CEO, BridgeBio

Those are smaller indications. Certainly, every minute matters for those patients as well, so we will go as quickly as possible. But for Fukuyama and some of the others, we probably have to do a little bit more work in terms of a phase II, just to make sure that we can derive a signal. What that natural history looks like is a little less well-documented than the broader 2I population, so designing the study appropriately will take a little bit of doing. But yeah, we certainly will pursue those opportunities.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Next in order is achondroplasia, PDUFA is in February, early February. What do you think is the low-hanging fruit? Obviously, there's the BioMarin compound already in the market in the U.S., but initially, once you're approved, I can think of three subgroups as naive patients, never tried, patients who have maybe discontinued, or patients who are on these CNP drugs. So where's the low-hanging fruit in your view, in the first view?

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, I think you rightly say there's a huge latent population in the United States right now that is not trying therapy. I think that's a big opportunity for us, so the, quote, unquote, "naive patients." I think a subpopulation of those are needle phobics or people who would rather not take a daily injection or a weekly injection, and another subpopulation are those that are struggling with the efficacy profile of the already approved products. Our product with superior efficacy, superior safety, and ultimately much more convenient ROA, being oral, I think should unlock that. Yet we do anticipate quite a bit of switching as well.

I mean, I think this is a category where, although I just said what I said about analog and moving second, in this case, we're third to market, this is a dramatically superior product as compared to the CNPs, from the biochemistry, from the genetics of what we know about the condition, to the mouse model, to every clinical experiment, to every point estimate you can look at, to the three New England Journal papers that we put out here. So, we anticipate and would expect from ourselves that we would gain a majority share of this marketplace over time.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yep, that was my next question, so okay. Speaking of pricing power, obviously, again, there's a precedent with these two analogs, but you have an oral. I think you've hit stat sig on proportionality. Seems differentiated to me. So, is there pricing power in your view, or should we kind of view the CNPs as the precedent here for your price?

Neil Kumar
Co-founder and CEO, BridgeBio

It certainly will be the precedent. How we think about pricing always just gets down to access for patients, and I think it can be sometimes confusing that a higher price will garner more access, certainly in the U.S. for patients. So we will keep an eye out for that. We have not made any final decisions there. But we do believe it is a superior product, so it could command premium pricing.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. Separately, this compound is going after HCH.

Neil Kumar
Co-founder and CEO, BridgeBio

Yep.

Andrew Tsai
Senior Biotech Analyst, Jefferies

You have a phase II/III study. Ultimately, in the phase III placebo-controlled portion, ultimately, are you expecting superior efficacy as well compared to

Neil Kumar
Co-founder and CEO, BridgeBio

In hypochondroplasia? Yes.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yes.

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, we would expect across the board, again, given the fact that you have gain-of-function mutations in FGFR3, so we are targeting both of the causal pathways, JAK-STAT and MAPK. It should ultimately translate into superiority. Obviously, the primary endpoint, which is change from baseline and height velocity, is quite noisy, even noisier in HCH. So how those point estimates play out, we will have to see. But again, I think what you will see from this molecule is the ability to affect a broader diaspora of symptomatology that these kiddos are afflicted with. The things that we have been publishing on, like sleep apnea, like reduction in ear infections, those are things that may not have made the New England Journal, but they are just huge, huge deals to the community that we are trying to serve.

When you have reductions like that, 40%, 50%, it is quite remarkable, and I think you should see that again in the HCH setting.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, great. You mentioned the same compounds going after SHOX, Turner.

Neil Kumar
Co-founder and CEO, BridgeBio

Yep

Andrew Tsai
Senior Biotech Analyst, Jefferies

A younger achondroplasia subgroup. Can you remind us the timelines for those programs?

Neil Kumar
Co-founder and CEO, BridgeBio

Those phase IIs will all commence in 2027 on SHOX and Turner, and the pediatric study is underway.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, perfect. Moving on to ADH1, because I want to make sure we talk about that. Encaleret PDUFA May of next year. Looks like maybe there are 3,000- 5,000 currently addressable in the U.S., 600 of them genetically confirmed and identified. By the time you launch in Q2, again, why wouldn't there be a bolus, or do you think there could be a bolus for this indication, especially because there's no drugs approved, I think?

Neil Kumar
Co-founder and CEO, BridgeBio

That's right. This will be the first drug product approved for ADH1 patient population. I would say this one looks a little different in that it's not really as concentrated. There's really not an MDA center of excellence, 160 centers that you can isolate. There are centers with large numbers of patients, but that tail is more uniform on this launch. I expect this launch to be a little bit more like a slow build. What's remarkable about mutations in the calcium-sensing receptor is if you look at any of the databases, there's some 12,000 patients in the United States alone with them, but we just haven't done a good job of identifying them. Now our hope is with this drug product, and again, free genetic testing, we should be able to find many more patients that could be helped here.

I think the other thing is there's just a growing understanding of how severe this disease condition could be. There was a publication just six months ago out of the U.K. showing that, and following patients longitudinally, showing that almost 80% of them were afflicted by downstream, pretty severe renal disease that limited lifespan to about average age of 57. People forget because the serum calcium diminution is what's driving a lot of the acute symptomatology, like seizures, brain fog, things of that nature, but the high levels of urine calcium really can drive a lot of downstream effects that we need to get around. We just published a paper about two weeks ago showing that 100% of patients on the trial improved by their own PRO in at least one or more symptoms.

That's pretty remarkable that people are feeling better, 100% of patients on that drug are feeling better. Again, consistent with the fact that 76% of patients were fully normalized in terms of serum and urine calcium, and that's really the power of this drug product.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. Curious, if you were to compare these three upcoming launches, which program takes the most market-building effort in your view? Or are these all pretty easy?

Neil Kumar
Co-founder and CEO, BridgeBio

Definitely not easy, no. I think we've proven that we can enter a competitive marketplace and help to grow it. We've done that in ATTR cardiomyopathy, and I'm pleased to see something between 5,500 and 6,000 new patients entering that funnel every quarter. I think that's been remarkable, and that's been a combined effort between us, Alnylam, and Pfizer. But I think in the context of achondroplasia, that's what gives me a lot of hope. We have a playbook. We sort of know what we're doing there. I think in terms of first to market, we're very focused on building our capability there. But there's a real capability that needs to be built in and around education, in and around genetic testing. I think there'll be some challenges that arise, but I'm excited for those launches.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. Sticking with ADH1, hypoparathyroidism you mentioned earlier, that has phase III data, year-end 2027, early 2028. I guess the simple question is, do you expect superiority over the Ascendis compound ultimately?

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah, I actually, I brought a slide if I can-

Andrew Tsai
Senior Biotech Analyst, Jefferies

Sure

Neil Kumar
Co-founder and CEO, BridgeBio

put it up. I do not know if it will go up. Because I have been deeply perplexed as to why this is not getting any attention. I mean, this is an oral, this would be the first oral in this category. We believe it potentially superior to the existing Ascendis product, and the biology makes sense. I am not sure what everyone is missing, but I am going to try a new slide here, just to try to articulate at least our enthusiasm and excitement around it. It really starts with the concept that the calcium-sensing receptor is expressed in the kidney, and in a PTH-independent way, regulates serum and urine calcium. It is in the thick ascending limb. We know it to be the case that it regulates calcium in the context of mutations and in the absence of mutations.

If you look on the left-hand side, that is the biochemistry of how it does it through claudin-14 signaling, and we can go through the details on that if that is of interest. You also can go to clinical trials. It is not just the ADH1 clinical trial, because a lot of people would say, "Well, there were gain-of-function mutations in the calcium receptor there." On the other hand, it has also been studied, calcilytic agents, in almost 1,300 osteoporotic patients. In all cases, we see the impact on serum and urine calcium. Recall, in hypopara, excuse me, a lot of hypos, hypopara, you actually have a condition that relates back to the aberrant regulation of serum and urine calcium.

You do not have to take the 10 patients, obviously, that is a small study with 80% fully normalizing urine and serum calcium, but you can look at a much broader data set to see that inhibition of the calcium-sensing receptor should lead to homeostatic normalization of serum and urine calcium. Now, how does that make it a superior product to the Ascendis product? It does so in two ways. Number one, it affects or impacts urine calcium in ways that that product does not and has been shown not to. You can see some of the numbers on the left-hand side, I am looking backwards now, of the slide. But it is also true that there is many patients here that are osteoporotic or otherwise have bone conditions that in the long- term, because PTH is pulling calcium from the bone, can be problematic for that disease condition.

Our early market research suggests 30%-35% of patients would actually want to use an oral product here that has this type of efficacy. Recall, really, really safe. We saw that in ADH1. There are people who are heterozygous loss of function or full loss of function for CaSR, and they are fine over long periods of time.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. ADH1, 12,000 U.S. patient market. How big is hypoparathyroidism?

Neil Kumar
Co-founder and CEO, BridgeBio

Like 80,000-90,000.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. It is even more. Okay.

Neil Kumar
Co-founder and CEO, BridgeBio

Yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

All right. I think we will wrap it up there, Neil.

Neil Kumar
Co-founder and CEO, BridgeBio

Okay.

Andrew Tsai
Senior Biotech Analyst, Jefferies

It has been a pleasure to see your company evolve into a very diversified company. Good luck on the launches coming up.

Neil Kumar
Co-founder and CEO, BridgeBio

Thanks, Andrew.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thanks, everyone.